Literature DB >> 21279417

SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-γ by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts.

Barbara Renga1, Andrea Mencarelli, Marco Migliorati, Sabrina Cipriani, Claudio D'Amore, Eleonora Distrutti, Stefano Fiorucci.   

Abstract

OBJECTIVE: The regulation of hepatic stellate cells (HSCs) by bacterial lipopolysaccharide (LPS) represents a recently-discovered and novel mechanism for hepatic injury and fibrosis. Stimulation of HSCs with LPS results in a rapid and marked induction of interleukin (IL)1β, IL6 and tumor necrosis factor α. These events lead to the development of the activated phenotype in the HSCs associated with fibrosis and inflammation in the injured liver. We have previously demonstrated that farnesoid X receptor (FXR) activation increases transcription of rat peroxisome proliferator-activated receptor-γ (PPARγ) gene in HSCs. We aimed at evaluating the molecular mechanism of the transcriptional regulation of the PPARγ gene by FXR.
METHODS: Real-time PCR, ELISA, transactivations, EMSA and ChIP experiments were performed in HSC-T6 cells, in primary HSCs, in HEK293T cells and in CCl(4)-treated rats.
RESULTS: In vivo and in vitro activation of FXR downregulates cytokines and collagen(α)1 while inducing PPARγ and small heterodimer partner (SHP). NUBIScan analysis of rat PPARγ promoter revealed the presence of a putative FXR response element. Cotransfection with FXR/retinoic acid receptor significantly enhanced chenodeoxycholic acid-induced luciferase activity. EMSA experiments demonstrated that FXR was able to bind to an inverted repeat-1 sequence and ChIP experiments confirmed that FXR is recruited on the PPARγ promoter.
CONCLUSION: The present study provides a molecular basis for the physiological cross-talk between FXR and PPARγ pathways in HSCs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21279417     DOI: 10.1007/s00011-010-0306-1

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  38 in total

1.  Antiatherosclerotic effect of farnesoid X receptor.

Authors:  Andrea Mencarelli; Barbara Renga; Eleonora Distrutti; Stefano Fiorucci
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-11-21       Impact factor: 4.733

2.  The bile acid sensor FXR regulates insulin transcription and secretion.

Authors:  Barbara Renga; Andrea Mencarelli; Piero Vavassori; Vincenzo Brancaleone; Stefano Fiorucci
Journal:  Biochim Biophys Acta       Date:  2010-01-07

3.  Pregnane X receptor is a target of farnesoid X receptor.

Authors:  Diana Jung; David J Mangelsdorf; Urs A Meyer
Journal:  J Biol Chem       Date:  2006-05-08       Impact factor: 5.157

4.  The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo.

Authors:  Giovanni Rizzo; Moises Disante; Andrea Mencarelli; Barbara Renga; Antimo Gioiello; Roberto Pellicciari; Stefano Fiorucci
Journal:  Mol Pharmacol       Date:  2006-06-15       Impact factor: 4.436

5.  Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells.

Authors:  Yong-Han Paik; Robert F Schwabe; Ramón Bataller; Maria P Russo; Christian Jobin; David A Brenner
Journal:  Hepatology       Date:  2003-05       Impact factor: 17.425

6.  A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis.

Authors:  B Goodwin; S A Jones; R R Price; M A Watson; D D McKee; L B Moore; C Galardi; J G Wilson; M C Lewis; M E Roth; P R Maloney; T M Willson; S A Kliewer
Journal:  Mol Cell       Date:  2000-09       Impact factor: 17.970

7.  The impact of pregnane X receptor activation on liver fibrosis.

Authors:  M C Wright
Journal:  Biochem Soc Trans       Date:  2006-12       Impact factor: 5.407

Review 8.  Monocytes and macrophages as cellular targets in liver fibrosis.

Authors:  Felix Heymann; Christian Trautwein; Frank Tacke
Journal:  Inflamm Allergy Drug Targets       Date:  2009-09

9.  Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.

Authors:  Inés Pineda Torra; Thierry Claudel; Caroline Duval; Vladimir Kosykh; Jean-Charles Fruchart; Bart Staels
Journal:  Mol Endocrinol       Date:  2003-02

Review 10.  Nuclear receptors and the control of metabolism.

Authors:  Gordon A Francis; Elisabeth Fayard; Frédéric Picard; Johan Auwerx
Journal:  Annu Rev Physiol       Date:  2002-05-01       Impact factor: 19.318

View more
  17 in total

Review 1.  Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis.

Authors:  Justin D Schumacher; Grace L Guo
Journal:  Handb Exp Pharmacol       Date:  2019

Review 2.  Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside.

Authors:  Feng Zhang; Desong Kong; Yin Lu; Shizhong Zheng
Journal:  Cell Mol Life Sci       Date:  2012-06-15       Impact factor: 9.261

Review 3.  Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease.

Authors:  Ting-Ying Jiao; Yuan-di Ma; Xiao-Zhen Guo; Yun-Fei Ye; Cen Xie
Journal:  Acta Pharmacol Sin       Date:  2022-02-25       Impact factor: 7.169

4.  Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.

Authors:  Nancy Magee; An Zou; Priyanka Ghosh; Forkan Ahamed; Don Delker; Yuxia Zhang
Journal:  J Biol Chem       Date:  2019-12-12       Impact factor: 5.157

5.  Liver fibrogenesis in non-alcoholic steatohepatitis.

Authors:  Zhaolian Bian; Xiong Ma
Journal:  Front Physiol       Date:  2012-07-11       Impact factor: 4.566

6.  Nuclear receptor variants in liver disease.

Authors:  Roman Müllenbach; Susanne N Weber; Frank Lammert
Journal:  J Lipids       Date:  2011-12-21

Review 7.  Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease.

Authors:  Ronan Thibaut; Matthew C Gage; Inès Pineda-Torra; Gwladys Chabrier; Nicolas Venteclef; Fawaz Alzaid
Journal:  FEBS J       Date:  2021-05-02       Impact factor: 5.622

8.  The orphan nuclear receptor small heterodimer partner is required for thiazolidinedione effects in leptin-deficient mice.

Authors:  Hsiu-Ting Tseng; Young Joo Park; Yoon Kwang Lee; David D Moore
Journal:  J Biomed Sci       Date:  2015-05-08       Impact factor: 8.410

Review 9.  Novel bile acid therapeutics for the treatment of chronic liver diseases.

Authors:  Vinod S Hegade; R Alexander Speight; Rachel E Etherington; David E J Jones
Journal:  Therap Adv Gastroenterol       Date:  2016-02-17       Impact factor: 4.409

10.  SUMOylation of PPARγ by rosiglitazone prevents LPS-induced NCoR degradation mediating down regulation of chemokines expression in renal proximal tubular cells.

Authors:  Ying Lu; Qiao Zhou; Yongbing Shi; Jian Liu; Fang Zhong; Xu Hao; Cong Li; Nan Chen; Weiming Wang
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.